Clinical Trial

Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study

Study acronym: SARCOPA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-03.
Trial Details
NCT Number NCT07285226
Lead Sponsor Center for Health Sciences, Serbia
Conditions Sarcopenia
Enrollment 30 participants
Start Date 2025-12-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-02